로그인 회원가입
icon_bulk_order대량 주문 Acrobiosystems for English
0
장바구니가 비어 있습니다
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: > CD79B

CD79B

요약

Name:B-cell antigen receptor complex-associated protein beta chain
Target Synonym:B-Cell Antigen Receptor Complex-Associated Protein Beta Chain,B29,Immunoglobulin-associated B29 protein,Ig-beta,B-cell-specific glycoprotein B29,CD79B,CD79b Molecule,CD79b Molecule, Immunoglobulin-Associated Beta,IGB,CD79B Antigen (Immunoglobulin-Associated Beta),CD79b Antigen,AGM6
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:9
Lastest Research Phase:Approved

제품 리스트 구매

일부의 생물활성 데이터

SCCHO-ATP171-Cell-based assay
 CD79B FACS

Expression analysis of human CD79B on CHO/Human CD79B Stable Cell Line by FACS.
Cell surface staining was performed on CHO/Human CD79B Stable Cell Line or negative control cell using APC-labeled anti-human CD79B antibody.

CDB-H52H3-SPR
 CD79B SPR

Polatuzumab captured on Protein G Chip can bind Human CD79B, His Tag (Cat. No. CDB-H52H3) with an affinity constant of 1.97 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

CDB-H82E3-ELISA
 CD79B ELISA

Immobilized Biotinylated Human CD79B, His,Avitag (Cat. No. CDB-H82E3) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Anti-CD79B (Polatuzumab) Humanized Antibody with a linear range of 0.1-2 ng/mL (Routinely tested).

Synonym Name

CD79b,B29,IGB,Ig-beta

Background

B-cell antigen receptor complex-associated protein beta chain (CD79b) is also known as B-cell-specific glycoprotein B29, Ig-beta,Immunoglobulin-associated B29 protein, B29 and IGB, which is a single-pass type I membrane protein containing one Ig-like V-type ( immunoglobulin-like ) domain and one ITAM domain.CD79b is required in cooperation with CD79A for initiation of the signal transduction cascade activated by the B-cell antigen receptor complex (BCR).CD79b can enhance phosphorylation of CD79A, possibly by recruiting kinases which phosphorylate CD79A or by recruiting proteins which bind to CD79A and protect it from dephosphorylation. Defects in CD79b are the cause of agammaglobulinemia type 6 (AGM6) that is a primary immunodeficiency characterized by profoundly low or absent serum antibodies and low or absent circulating B cells due to an early block of B-cell development.

Clinical and Translational Updates

공개 약품 정보

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Polatuzumab vedotin RG-7596; RO-5541077-000; FCU-2711; DCDS-4501A; RO-5541077 Approved Seattle Genetics Inc, Genentech Inc Polivy Japan Lymphoma, Large B-Cell, Diffuse F. Hoffmann-La Roche Ag 2019-06-10 Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell Details

임상 약품 정보

Name Research Code Research Phase Company Indications Clinical Trials
NBT-508 Phase 1 Clinical Newbio Therapeutics Inc Lymphoma, B-Cell; Lymphoma, Non-Hodgkin Details
Iladatuzumab vedotin DCDS-0780A; RO-7032005 F. Hoffmann-La Roche Ltd Details
TolDCB29 Phase 2 Clinical Umc Utrecht Arthritis, Rheumatoid Details
CD19/79b Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) bi-4SCAR CD19/79b Phase 2 Clinical Shenzhen Geno-Immune Medical Institute Lymphoma, B-Cell Details
PRV-3279 MGD-010; PRV-3279; CD32BxCD79B Phase 2 Clinical Macrogenics Inc Drug-Related Side Effects and Adverse Reactions Details

This web search service is supported by Google Inc.

totop